Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05669846
Title Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Diwakar Davar
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.